ADC Therapeutics SA Shares Outstanding 2019-2022 | ADCT

ADC Therapeutics SA shares outstanding from 2019 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
ADC Therapeutics SA Annual Shares Outstanding
(Millions of Shares)
2021 77
2020 65
2019 49
2018 47
ADC Therapeutics SA Quarterly Shares Outstanding
(Millions of Shares)
2022-06-30 77
2022-03-31 77
2021-12-31 77
2021-09-30 77
2021-06-30 77
2021-03-31 77
2020-12-31 65
2020-09-30 71
2020-06-30 63
2020-03-31 51
2019-12-31
2019-09-30 51
2019-06-30 48
2018-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.034B
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.286B 9.60
GSK (GSK) United Kingdom $71.707B 8.61
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.077B 18.55
Biohaven Pharmaceutical Holding (BHVN) United States $10.582B 0.00
Ginkgo Bioworks Holdings (DNA) United States $6.645B 0.00
Arcus Biosciences (RCUS) United States $1.982B 38.68
Myovant Sciences (MYOV) United Kingdom $1.693B 0.00
Emergent Biosolutions (EBS) United States $1.465B 8.49
Zymeworks (ZYME) Canada $0.405B 0.00
Enzo Biochem (ENZ) United States $0.132B 0.00
Gelesis Holdings (GLS) United States $0.101B 0.00
Ambrx Biopharma (AMAM) United States $0.099B 0.00
SQZ Biotechnologies (SQZ) United States $0.096B 0.00